SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).
Kathleen N. Moore
Consultant or Advisory Role - AstraZeneca
Paul DiSilvestro
Research Funding - AstraZeneca
Elizabeth S. Lowe
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Sally Garnett
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Eric Pujade-Lauraine
No relevant relationships to disclose